Clinical trials
Every registered trial of Thymosin Alpha-1
46 studies, 11 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Thymosin Alpha-1 has a real but limited body of human research.
- 46 registered studies in total.
- 11 are still enrolling people, so this is active research, not just history.
What kind of research
- 45 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 9,820 people took part in those.
- A further 1 study only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.
How far along it is
- 11 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 12 have published results in the medical literature that anyone can read.
- The research spans 14 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 46 of 46 trials for Thymosin Alpha-1.
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
Nanjing Medical University
Aortic Aneurysm and Dissection
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
The Affiliated Hospital of Putian University
Esophageal Cancer
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
Beijing Friendship Hospital
MCRC
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The Methodist Hospital Research Institute
Vaccine Response · COVID-19 Vaccine · Immune Response to Covid 19 Vaccination
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Xuanwu Hospital, Beijing
Resectable Non-Small-Cell Lung Cancer
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
The First Affiliated Hospital of Xiamen University
Hematological Malignancy · Lymphocytopenia
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Ruijin Hospital
Carcinoma, Pancreatic Ductal
Immuno-effect of Tα1 for Stage I NSCLC
Yousheng Mao
Non Small Cell Lung Cancer
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Zekuan Xu
Gastric Cancer · Esophagogastric Junction Adenocarcinoma
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
Tongji Hospital
Cervical Cancer · Gynecologic Malignancies · Endometrial Cancer
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
Locally Advanced Rectal Cancer
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
Fudan University
Esophageal Squamous Cell Carcinoma
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
Colorectal Neoplasms
Thymosin Alpha-1 for irAE Secondary to ICIs
Jun Wang
IrAE
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
Non-small Cell Lung Cancer
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Advanced Solid Tumor · Refractory Tumor
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Respiratory Distress Syndrome
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
SC-Ta1-CF-001
Sciclone Pharmaceuticals International (SG) Pte. Ltd.
Cystic Fibrosis
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
Shanghai Public Health Clinical Center
HIV-1-infection
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Fudan University
Stage II Colorectal Cancer · Stage III Colorectal Cancer
Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
William B. Ershler, MD
COVID-19
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
Rhode Island Hospital
Covid19
The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF
Sun Yat-sen University
Liver Failure
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
EGFR Mutation Positive Non Small Cell Lung Cancer
The Efficacy and Safety of Ta1 for Sepsis
Sun Yat-sen University
Sepsis
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
SciClone Pharmaceuticals
Non-Small Cell Lung Cancer
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
First People's Hospital of Hangzhou
Lung Adenocarcinoma
Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis
Sun Yat-sen University
Sepsis
Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery
University Hospital, Lille
Pregnancy Complications · Hemorrhage
Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
Zhejiang Provincial People's Hospital
Non-small Cell Lung Cancer · Metastatic Non-small Cell Lung Cancer · Radiotherapy · Thymalfasin
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Hangzhou Cancer Hospital
Esophageal Cancer · Metastatic Esophageal Cancer · Stereotactic Body Radiation Therapy · Thymalfasin
Abscopal Effect for Metastatic Small Cell Lung Cancer
Zhejiang Provincial People's Hospital
Small Cell Lung Cancer · Radiotherapy · Thymalfasin
Abscopal Effect for Metastatic Colorectal Cancer
Zhejiang Provincial People's Hospital
Colorectal Cancer · Metastatic Colorectal Cancer · Thymalfasin
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
Jia Fan
Curable Hepatitis B Virus-Related Hepatocellular Carcinoma
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Beijing Friendship Hospital
Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Beijing Friendship Hospital
Liver Cirrhosis
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Replicor Inc.
Hepatitis B, Chronic
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
sigma-tau i.f.r. S.p.A.
END STAGE RENAL DISEASE
Dendritic Cell Based Therapy for Breast Cancer Patients
Inge Marie Svane
Breast Cancer
Efficacy of Thymosin alpha1 for Severe Sepsis
Sun Yat-sen University
Severe Sepsis
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
sigma-tau i.f.r. S.p.A.
Chronic Hepatitis C
Dendritic Cell Based Therapy of Renal Cell Carcinoma
Inge Marie Svane
Advanced Renal Cell Carcinoma
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Malignant Melanoma
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
SciClone Pharmaceuticals
Hepatitis C · Hepatitis C, Chronic
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
SciClone Pharmaceuticals
Carcinoma, Hepatocellular
The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Thymosin Alpha-1 is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.